Vaccination against Herpes Zoster Virus: awareness, Benefits for the General Population
No Thumbnail Available
Date
2020
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Herpes Zoster (HZ) ir slimība, ko izraisa vējbaku zoster vīrusa (VZV) reaktivācija, kas parasti izpaužas kā sāpīgi elementi uz ādas kas lokalizēts vienā dermatomā, kas nešķērso viduslīniju. Tā ir izplatīta slimība, īpaši pacientiem, kas vecāki par 50 gadiem. HZ ir saistīts ar daudzām komplikācijām, un viena no tām ir postherpētiskā neiralģija, kas ir visizplatītākā un kam ir vislielākā ietekme uz dzīves kvalitāti. Pasākumi, lai novērstu HZ, ietver izvairīšanos no saskares, imūnglobulīna lietošanu un vakcināciju. Ir pierādīts, ka vakcīna efektīvi samazina HZ un postherpētiskās neiralģijas sastopamību, un tā ir ieteicama pacientiem, kas vecāki par 50 gadiem.
Herpes zoster (HZ) is a disease caused by the reactivation of varicella zoster virus (VZV), that appears as a painful eruption in the skin bounded to one dermatome and not crossing the midline. Nowadays, it presents as a common disease, especially in patients older than 50 years. HZ is associated with many complications, one of which, post herpetic neuralgia, is the most common and has the biggest impact on quality of life. Measures to prevent HZ include avoidance of contact, immunoglobulins and vaccination. The vaccine has been shown to be efficacious in decreasing the incidence of herpes zoster and post herpetic neuralgia and it is suggested in patients older than 50 years of age.
Herpes zoster (HZ) is a disease caused by the reactivation of varicella zoster virus (VZV), that appears as a painful eruption in the skin bounded to one dermatome and not crossing the midline. Nowadays, it presents as a common disease, especially in patients older than 50 years. HZ is associated with many complications, one of which, post herpetic neuralgia, is the most common and has the biggest impact on quality of life. Measures to prevent HZ include avoidance of contact, immunoglobulins and vaccination. The vaccine has been shown to be efficacious in decreasing the incidence of herpes zoster and post herpetic neuralgia and it is suggested in patients older than 50 years of age.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Shingrix, Zostavax, herpes zoster, herpes zoster vaksīnas, postherpētiskās neiralģijas, herpes zoster, herpes zoster vaccine, Shingrix, Zostavax, postherpetic neuralgia